Travere Therapeutics (TVTX) Stock
Travere Therapeutics (TVTX) closed at $51.10 on Nov 17, 2026; its Tenet Score is 43 of 100 against 340 Healthcare peers.
29 figures withheld by our checks. Each blank figure names its reason.
Key stats
- Close
- $51.10
- Nov 17, 2026
- Market cap
- $4.8B
- share price × the latest quarter's diluted weighted-average share count (vendor)
- 52-week range
- 22.59 – 68.73
- low → high · as of close, Nov 16, 2026
- Tenet Score
- 43/100
- Weak · 340 Healthcare peers
Industry: Drugs
Travere Therapeutics Inc scores 43/100. Weak. Strongest on growth, value is the soft spot versus 340 Healthcare peers.
Tenet Score · vs sector
n=340Factor grades
Price
The whole report, at a glance · every card is a live peek, click any to open the section
- ~ Piotroski F-Score
- ✕ Graham Defensive
- ✕ Quality Compounder
- ~ Drawdown Context
- ~ Reversal Evidence
- ✕ Not-a-Value-Trap Gate
13F flows & insider trades land here.
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeo…
Similar-sized companies in Drugs
The 10 companies in this industry closest in market cap, as of Nov 16, 2026.
| Company | Tenet Score | Market cap |
|---|---|---|
| PTC Therapeutics IncPTCT | 57 | $5.1B |
| Liquidia CorpLQDA | 55 | $5.0B |
| Dianthus Therapeutics IncDNTH | 63 | $5.0B |
| Edgewise Therapeutics IncEWTX | 69 | $4.8B |
| Cogent Biosciences IncCOGT | 33 | $4.8B |
| Ionis Pharmaceuticals IncIONS | 27 | $4.7B |
| Definium Therapeutics Inc.DFTX | 50 | $4.1B |
| CRISPR Therapeutics AGCRSP | 64 | $3.9B |
| Tarsus Pharmaceuticals IncTARS | 34 | $3.9B |
| Xenon Pharmaceuticals IncXENE | 44 | $3.9B |
Common questions
What sector and industry is Travere Therapeutics in?
Travere Therapeutics is in the Healthcare sector and the Drugs industry.
What is Travere Therapeutics' Tenet Score?
Travere Therapeutics' Tenet Score is 43 out of 100, ranked against 340 Healthcare peers as of Nov 16, 2026.




